Citi upgrades BioAge Labs to Buy on potential in obesity

Citi analyst Samantha Semenkow upgraded BioAge Labs (BIOA) to Buy from Neutral with a price target of $10, up from $5. The firm believes the company’s BGE-102, an oral NLRP3 inhibitor being developed for obesity, could be “differentiating.” BGE-102 is a “potentially differentiated” NLRP3 inhibitor that could be given in combination with oral GLP1s or be a monotherapy, the analyst tells investors in a research note.